Indications for RETROVIR IV:
HIV-1 infection, in combination with other antiretroviral agents. Prevention of maternal-fetal HIV-1 transmission.
Give by IV infusion over 1hr; use only until oral therapy can be given. 1mg/kg every 4hrs. Renal impairment (CrCL <15mL/min) or on dialysis: 1mg/kg every 6–8hrs. Prevention of maternal-fetal HIV or vertical transmission, severe anemia and/or neutropenia: see full labeling.
Vertical transmission: see full labeling.
Hematological toxicity. Myopathy. Lactic acidosis and severe hepatomegaly with steatosis.
RETROVIR IV Warnings/Precautions:
Risk of hematologic toxicity/bone marrow suppression; monitor CBCs esp. in advanced HIV-1 disease; interrupt dose if anemia or neutropenia occurs. Myopathy/myositis with prolonged use. Suspend if lactic acidosis or pronounced hepatotoxicity (eg, hepatomegaly, steatosis) occurs. Monitor for lipoatrophy; use alternatives if suspected. Severe renal impairment: reduce dose (see Adult). Hepatic impairment or cirrhosis: monitor for hematologic toxicity. Latex allergy (IV). Women. Obesity. Elderly. Pregnancy. Nursing mothers: not recommended.
RETROVIR IV Classification:
Nucleoside analogue (reverse transcriptase inhibitor).
RETROVIR IV Interactions:
Avoid concomitant stavudine, doxorubicin, nucleoside analogues (eg, ribavirin). Increased hematologic toxicity with ganciclovir, interferon alpha, ribavirin, other bone marrow suppressants or cytotoxic drugs. Monitor for treatment-associated toxicities (eg, hepatic decompensation) with interferon alpha with or without ribavirin.
Headache, malaise, nausea, vomiting, anorexia; neutropenia, anemia, myopathy, lactic acidosis, severe hepatomegaly with steatosis, immune reconstitution syndrome, pancreatitis, lipoatrophy. Children: also fever, cough.
Generic Drug Availability:
Tabs—contact supplier; Caps—100; Syrup—240mL; IV (20mL/vial)—1, 5